Cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer

Journal of biomedical science

Volumn 9, Issue 5, 2002, Pages 443-452

  Huang, Dong Ming ^a   Guh, Jih Hwa ^b   Huang, Yao Ting ^a   Chueh, Shih Chieh ^c   Wang, Hui Po ^d   Teng, Che Ming ^a  

^a Pharmacological Institute   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; OUABAIN; PACLITAXEL; TUBULIN;

ARTICLE; CELL CYCLE; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MALE; PHYSIOLOGY; PROSTATE TUMOR;

ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; OUABAIN; PACLITAXEL; PROSTATIC NEOPLASMS; TUBULIN;

EID: 0036725627     PISSN: 10217770     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02256539     Document Type: Article

References (38)

1. Banerjee A, Jordan MA, Luduena RF. Interaction of reduced gIutathione with bovine brain tubulin. Biochem Biophys Res Commun 128: 506-512; 1985.
2. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8:465-475; 1994.
3. Bray PG, Ward SA. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium faIciparum. Pharmacol Ther 77: 1-28; 1998.
4. Dumontet C, Sikic BL Mechanisms of action and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070; 1999.
5. Friedland D, Cohen J, Miller R. A phase II trial of taxotere in hormone refractory prostate cancer. Proc ASCO 18:1237; 1999.
6. 3H]noradrenaline release in human prostate. J Urol 163: 338-342; 2000.
7. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182; 1994.
8. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. TaxoI: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55-61; 1993.
9. Horwitz SB, Lothenstein L, Manfredi J J, Meltado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zeheb R. Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 466:733-744; 1986.
10. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253-257; 1997.
11. Hyams JS, Lloyd CW. Microtubules. New York, Wiley-Liss, 1994.
12. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitax-el (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825; 1996.
13. Jordan MA, Wilson L. Microtubule and action filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130; 1998.
14. Kadi A, Pichard V, Lehmann M, Briand C, Braguer D, Marvaldi J, Rognoni JB, Luis J. Effect of microtubule disruption on cell adhesion and spreading. Biochem Biophys Res Commun 246:690-695; 1998.
15. Kang MH, Figg WD, Dabut W. Taxanes in hormone-refractory prostate cancer. Cancer Pract 7:270-272; 1999.
16. Larsen AK, Escarqueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217-229; 2000.
17. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53: 2066-2070; 1993.
18. Martiney JA, Ceranli A, Slater AFG. Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodiurn falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 270: 22393-22398; 1995.
19. Murata Y, Matsuda T, Tamada K, Hosoi R, Asano S, Taknma K, Tanaka K, Baba A. Ouabain-induced cell proliferation in cultured rat astrocytes. Jpn J Pharmaco 172: 347-353; 1996.
20. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391: 199-203; 1998.
21. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85: 290-297; 1994.
22. Pamess J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 91: 479-487; 1981.
23. Picus J, Schultz M, Cochrane J. A phase II1 trail of docetaxei in patients with hormone refractory prostate cancer (HRPC): Long term results. Proc ASCO 18: 1206; 1999.
24. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotypes in human prostate carcinoma ceils as a result of estramustine resistance. Cancer Res 56: 2584-2589; 1996.
25. Roepe PD, Martiney JA. Are ion-exchange processes central to understanding drug-resistance phenomena? Trends Pharmacol Sci 20: 62-65; 1999.
26. Roth B J, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460; 1993.
27. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374; 1997.
28. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52: 35-84; 1991.
29. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 332: 1004-1014; 1995.
30. Schiff PB, Fant J, Horwitz SB. Promotion of micrombule assembly in vitro by taxol. Nature 277: 665-667; 1979.
31. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565; 1980.
32. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26(5 suppl 17): 3-7; 1999.
33. Strobel T, Kraeft SK, Chert LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: A novel role for BAX during chemotherapy-induced cell death. Cancer Res 58: 4776-4781; 1998.
34. Thatte SH, Bridges KR, Golan DE. Microtubule inhibitors differentially affect translational movement, cell surface expression and endocytosis of transferrin receptors in K562 cells. J Cell Physio 1160: 345-357; 1994.
35. Tishler RB, Lamppu DM, Park S, Price BD. Microtubule-active drugs taxol, vinbtastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55: 6021-6025; 1995.
36. Verheye-Dua FA, Bohm L. Influence of apoptosis on the enhancement of radiotoxicity by ouabain. Strahlenther Onkol 176:186-191; 2000.
37. Wang TH, Wang HS, Soong YK. Paclitaxelinduced cell death: Where the cell cycle and apoptosis come together? Cancer 88: 2619-2628; 2000.
38. Wilson L, Jordan MA. Microtubule dynamics: Taking aim at a moving target. Chem Biol 2: 569-573; 1995.